Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-11-20
2011-11-29
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S235800, C514S252140, C514S252190, C514S275000, C544S058200, C544S060000, C544S061000, C544S122000, C544S295000, C544S331000
Reexamination Certificate
active
08067409
ABSTRACT:
Compounds that inhibit protein kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed.
REFERENCES:
patent: 0114375 (2001-03-01), None
patent: 02066480 (2002-08-01), None
patent: 02066481 (2002-08-01), None
patent: 03000682 (2003-01-01), None
patent: 2004110990 (2004-12-01), None
patent: WO2005068452 (2005-07-01), None
patent: WO2006044869 (2006-04-01), None
patent: WO2006068826 (2006-06-01), None
patent: 2006094236 (2006-09-01), None
patent: 2007123892 (2007-11-01), None
patent: 2008029152 (2008-03-01), None
Simone, Oncology: Introduction, Cecil Textbook of Medicine, 20th Edition, vol. 1, pp. 1004-1010, 1996.
Catrina S-B et al., “Insulin-like growth factor-I receptor activity is essential for Kaposi's sarcoma growth and survival”, Br. J. Cancer, vol. 92, pp. 1467-147, 2005.
Davies, D., “Targeting the Epidermal Growth Factor Receptor for Therapy of Carcinomas”, Biochem. Pharm. vol. 51 (9), pp. 1101-1110, 1996.
Druker, B., “Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome”, New England J of Medicine, vol. 344, p. 1038, 2001.
Hirota, S., “Gain of function Mutations of C-kit in Human Gastrointestinal Stromal Tumors”, Science, vol. 279, p. 577-580, 1998.
Hynes, N., “The biology of erbB-2
eu/HER-2 and its role in cancer”, Biochem. Biophys. Acta. vol. 1198, pp. 165-184, 1994.
Khandwala, H., “The Effects of Insulin-Like Growth Factors on Tumorigenesis and Neoplastic Growth”, Endocrine Reviews, vol. 21, (3), pp. 215-244, 2000.
Loewe, et al., “Ein nener Typ der 4-Amino-chinolin-Reihe”, Zrzeneim. Forsch, vol. 16,p. 1306-1310, 1966.
Lutz, M.P., “Overexpression and Activation of the Tyrosine Kinase Src in Human Pancreatic Carcinoma”, Biochemical & Biophysical Research Commun., vol. 243, pp. 503-508, 1998.
Mathis, G., “HTRF(R) Technology”, J. Biomol. Screen, vol. 4(6), pp. 309-314, 1999.
Pure Appl. Chem, “Rules for the Nomenclature of Organic Chemistry, Section E: Stereochemistry”, IUPAC Commission on Nomenclature of Organic Chemistry, Pergamon Press,vol. 45, pp. 13-20, 1976.
Rusch, V., “The Epidermal Growth Factor Receptor and Its Ligands as Therapeutic Targets in Human Tumors”, Cytokine & Growth Factor Rev. vol. 7, pp. 133-141, 1996.
Slamon, D., “Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer that Overexpresses HER2”, New England J. Med. vol. 344(11), pp. 783-792, 2001.
Summy, J., “Src family kinases in tumor progression and metastasis”, Cancer & Metastasis Rev. vol. 22, p. 337-358, 2003.
Talamonti, M., “Increase in Activity and Level of pp60 c-src in Progressive Stages of Human Colorectal Cancer”, J. Clin. Invest. vol. 91, pp. 53-60, 1993.
PCT Search Report for PCT/US2008/084469 mailed on Mar. 18, 2009.
Ba-Maung Nwe Y.
Bell Randy L.
Clark Richard F.
Erickson Scott A.
Fidanze Steve D.
Abbott Laboratories
Rao Deepak
Steele Gregory W.
Steele Susan L.
LandOfFree
Protein kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Protein kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protein kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4313156